MPR Weekly Dose 116 — First-in-Class T2D Treatment; FDA Decline Fluvoxamine; Booster Doses for Children; COVID-19, Influenza, and RSV Test; Wearable Furosemide Delivery System

<p><span style="font-weight: 400;">The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review.<br /></span></p>